Skin Tape Harvesting for Transcriptomics Analysis

Exclusion Criteria

• •1. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.
• •2. Evidence of skin conditions other than psoriasis that would interfere with the evaluations.
• •3. Use of systemic anti-psoriasis therapies within 28 days of study initiation, or three times the half-life of the drug, whichever is longer;
• •4. Use of UVB therapy or moderate strength non-steroidal topical treatments on lesion to be biopsied within 14 days of study initiation;
• •5. Current enrollment in investigational device or investigational drug trial(s), or receipt of any investigational agent(s) within 28 days before baseline visit;
• •6. Use of JAK inhibitor within 4 weeks of screening;
• •7. Known HIV-positive status or known history of any other immuno-suppressing disease;
• •8. Exposure to hepatitis B or hepatitis C or to high risk factors for hepatitis B or C, such as intravenous drug use in patient;
• •9. Pregnant or nursing females;
• •10. Subjects with a history of keloid formation or hypertrophic scarring;
• •11. Individuals who have lidocaine sensitivity.